Tianhu Wang
Papers
1
Total Citations
53
H-Index
1
About
Dr. Tianhu Wang is a leading clinical oncologist whose research focuses on neoadjuvant immunotherapy for resectable non-small cell lung cancer (NSCLC). His most impactful work investigates the synergistic potential of combining PD-1 inhibitors with chemotherapy prior to surgery, aiming to improve long-term survival outcomes for lung cancer patients. In his landmark 2021 open-label, multicenter, single-arm study, Dr. Wang demonstrated the safety and efficacy of this combined neoadjuvant approach, building upon pivotal trials like CheckMate 159. This work, which has garnered over 50 citations, provides critical evidence for integrating immunotherapy earlier in the treatment paradigm. By exploring how PD-1 blockade can prime the immune system before tumor resection, Dr. Wang’s contributions are helping to redefine standard-of-care protocols for operable NSCLC. His research addresses a key challenge in thoracic oncology: converting more patients to surgical candidates while reducing the risk of recurrence. For students and clinicians, Dr. Wang’s work exemplifies the translational power of combining immunotherapy with traditional modalities to achieve better outcomes in high-risk, resectable lung cancer.
Research Focus
Key Achievements
Top Papers
- 1